Connecting Innovation to Purpose

21 Phase 1 Summary - Data cutoff December 2023 Predicted therapeutically relevant doses in Ph. 1 study Objective Response Rate Disease Control Rate Tumor shrinkage across all nectin-4 positive mUC and cervical patients in study Dose for first observed SD Dose for first observed PR Longest observed response duration to-date Participants still on CRB-701 First expansion dose chosen Seven patients treated at 2.7mg/kg and 3.6 mg/kg on Q3W schedule 43%: 3 out of 7 patients with PR's (2 unconfirmed) 71%: 5 out of 7 patients 9 out of 10 patients 0.6 mg/Kg 1.2 mg/Kg 11 cycles (still ongoing) 7/18 (38%) 3.6 mg/Kg (cohort 6)

View entire presentation